Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 1

Status

Active not recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 24Stomach Neoplasms 10Pancreatic Neoplasms 10Rectal Neoplasms 9Colonic Neoplasms 9Adenocarcinoma Of Esophagus 8Esophageal Neoplasms 7Urinary Bladder Neoplasms 6Neoplasms 5Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Adenocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Cholangiocarcinoma 4Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Carcinoma 3Ovarian Neoplasms 2Melanoma 2Lung Neoplasms 2Hepatoblastoma 2Gallbladder Neoplasms 2Biliary Tract Neoplasms 2Anus Neoplasms 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1Urothelial Carcinoma of the Bladder 1Urologic Neoplasms 1

Interventions

pembrolizumab 31Paclitaxel 14Carboplatin 12Cisplatin 8lenvatinib 7Pemetrexed 5olaparib 4belzutifan 4Oxaliplatin 4Fluorouracil 4Docetaxel 4Capecitabine 4patritumab deruxtecan 3Leucovorin 3Gemcitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3Acetaminophen 3Saline Solution 2Levoleucovorin 2Irinotecan 2Histamine H2 Antagonists 2Histamine Antagonists 2Etoposide 2Dexamethasone 2Cetuximab 2130-nm albumin-bound paclitaxel 2zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Fluorouracil × 30 days × Clear all
NCT06469944 2026-05-26

MK-3475-06C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
160 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT05239741 2026-05-22

MK-3475-C66

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
100 enrolled
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT05152147 2026-05-19

HERIZON-GEA-01

Jazz Pharmaceuticals

Phase 3 Active not recruiting
920 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

NCT04210115 2026-05-13

KEYNOTE 975

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
703 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡